Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Assembly Biosciences (ASMB) over the last 11 years, with Q3 2025 value amounting to -$1.5 million.

  • Assembly Biosciences' Net Cash Flow fell 11592.38% to -$1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.9 million, marking a year-over-year decrease of 42951.0%. This contributed to the annual value of $18.5 million for FY2024, which is 15679.77% up from last year.
  • Assembly Biosciences' Net Cash Flow amounted to -$1.5 million in Q3 2025, which was down 11592.38% from $593000.0 recorded in Q2 2025.
  • Over the past 5 years, Assembly Biosciences' Net Cash Flow peaked at $18.8 million during Q1 2021, and registered a low of -$25.1 million during Q4 2021.
  • In the last 5 years, Assembly Biosciences' Net Cash Flow had a median value of -$1.1 million in 2024 and averaged -$1.9 million.
  • Data for Assembly Biosciences' Net Cash Flow shows a peak YoY increase of 52689.51% (in 2021) and a maximum YoY decrease of 231827.01% (in 2021) over the last 5 years.
  • Assembly Biosciences' Net Cash Flow (Quarter) stood at -$25.1 million in 2021, then soared by 91.03% to -$2.3 million in 2022, then tumbled by 202.22% to -$6.8 million in 2023, then surged by 245.15% to $9.9 million in 2024, then tumbled by 114.88% to -$1.5 million in 2025.
  • Its Net Cash Flow was -$1.5 million in Q3 2025, compared to $593000.0 in Q2 2025 and -$14.9 million in Q1 2025.